Contraception
Volume 82, Issue 1 , Pages 72-85 , July 2010

Contraceptive use among women with inflammatory bowel disease: A systematic review

  • Lauren B. Zapata

      Affiliations

    • Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
    • Corresponding Author InformationCorresponding author. Centers for Disease Control and Prevention, Atlanta, GA 30341, USA. Tel.: +1 770 488 6358; fax: +1 770 488 6391.
    • ,
  • Melissa E. Paulen

      Affiliations

    • Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
    • ,
  • Catherine Cansino

      Affiliations

    • Johns Hopkins Bayview Medical Center, Baltimore, MD 21223, USA
    • ,
  • Polly A. Marchbanks

      Affiliations

    • Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA
    • ,
  • Kathryn M. Curtis

      Affiliations

    • Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA 30341, USA

Received 4 February 2010 ,Accepted 4 February 2010.

References 

  1. Faculty of Family Planning and Reproductive Health Care Clinical Effectiveness Unit . Contraceptive choices for women with inflammatory bowel disease. J Fam Plann Reprod Health Care. 2003;29:127–134
  2. Peppercorn M. Definition of and risk factors for inflammatory bowel disease. In:  Basow D editors. UpToDate. Waltham (Mass): UpToDate; 2008;
  3. Herrinton LJ, Liu L, Lewis JD, Griffin PM, Allison J. Incidence and prevalence of inflammatory bowel disease in a Northern California managed care organization, 1996–2002. Am J Gastroenterol. 2008;103:1998–2006
  4. Jess T. Prognosis of inflammatory bowel disease across time and countries. Dan Med Bull. 2008;55:103–120
  5. Cornish JA, Tan E, Simillis C, Clark SK, Teare J, Tekkis PP. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103:2394–2400
  6. Danese S, Papa A, Saibeni S, Repici A, Malesci A, Vecchi M. Inflammation and coagulation in inflammatory bowel disease: the clot thickens. Am J Gastroenterol. 2007;102:174–186
  7. Wakefield A, Sawyerr A, Hudson M, Dhillon A, Pounder R. Smoking, the oral contraceptive pill, and Crohn's disease. Dig Dis Sci. 1991;36:1147–1150
  8. Bernstein C, Blanchard J, Houston D, Wajda A. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85:430–434
  9. Miehsler W, Reinisch W, Valic E, et al. Is inflammatory bowel disease an independent and disease specific risk factor for thromboembolism?. Gut. 2004;53:542–548
  10. Solem C, Loftus E, Tremaine W, Sandborn W. Venous thromboembolism in inflammatory bowel disease. Am J Gastroenterol. 2004;99:97–101
  11. Gosk-Bierska I, McBane R, Waszczuk E, Paradowski L, Wysokinski W. Prevalence of lower extremity venous disease in inflammatory bowel disease. Int Angiol. 2007;26:67–71
  12. Heinemann L, Dinger JC. Range of published estimates of venous thromboembolism incidence in young women. Contraception. 2007;75:328–336
  13. Nguyen G, Sam J. Rising prevalence of venous thromboembolism and its impact on mortality among hospitalized inflammatory bowel disease patients. Am J Gastroenterol. 2008;103:2272–2280
  14. Novotny D, Rubin R, Slezak F, Porter JA. Arterial thromboembolic complications of inflammatory bowel disease. Report of three cases. Dis Colon Rectum. 1992;35:193–196
  15. Wong T, Nightingale J, Winter M, Muller AF. Spontaneous venous thrombosis in inflammatory bowel disease: relevance of factor V Leiden and the prothrombin gene mutation. J Thromb Haemost. 2003;1:1326–1328
  16. Wexner D, Rosen L, Lowry A, et al. Practice parameters for the treatment of mucosal ulcerative colitis — supporting documentation. Dis Colon Rectum. 1997;40:1277–1285
  17. Gardiner K, Dasari B. Operative management of small bowel Crohn's disease. Surg Clin North Am. 2007;87:587–610
  18. Victor A, Odlind V, Kral J. Oral contraceptive absorption and sex hormone binding globulins in obese women: effects of jejunoileal bypass. Gastroenterol Clin North Am. 1987;16:483–491
  19. Hanker JP. Gastrointestinal disease and oral contraception. Am J Obstet Gynecol. 1990;163:2204–2207
  20. Thompson N, Driscoll R, Pounder R, Wakefield AJ. Genetics versus environment in inflammatory bowel disease. Br Med J. 1996;312:95–96
  21. Baird D, Narendranathan M, Sandler R. Increased risk of preterm birth for women with inflammatory bowel disease. Gastroenterology. 1990;99:987–994
  22. Marri SR, Ahn C, Buchman AL. Voluntary childlessness is increased in women with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:591–599
  23. Alstead E. Inflammatory bowel disease in pregnancy. Postgrad Med J. 2002;78:23–26
  24. Cornish JA, Tan E, Teare J, et al. A meta-analysis on the influence of inflammatory bowel disease on pregnancy. Gut. 2007;56:830–837
  25. Fonoger K, Sorensen H, Olsen J, Dahlerup JF, Rasmussen SN. Pregnancy outcome for women with Crohn's disease: a follow-up study based on linkage between national registries. Am J Gastroenterol. 1998;93:2426–2430
  26. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd edition. Geneva: World Health Organization; 2004;
  27. World Health Organization . Medical eligibility criteria for contraceptive use, 2008 update. Geneva: World Health Organization; 2009;Accessed July 9, 2009 (http://whqlibdoc.who.int/hq/2008/WHO_RHR_08.19_eng.pdf)
  28. Mohllajee AP, Curtis K, Flanagan RG, Rinehart W, Gaffield ML, Peterson HB. Keeping up with evidence: a new system for WHO's evidence-based family planning guidance. Am J Prev Med. 2005;28:483–490
  29. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35
  30. Cosnes J, Carbonnel F, Carrat F, Beaugerie L, Gendre J. Oral contraceptive use and the clinical course of Crohn's disease: a prospective cohort study. Gut. 1999;45:218–222
  31. Grimmer S, Back D, Orme M, Cowie A, Gilmore I, Tjia J. The bioavailability of ethinyloestradiol and levonorgestrel in patients with an ileostomy. Contraception. 1986;33:51–59
  32. Nilsson L, Victor A, Kral J, Johansson E, Kock N. Absorption of an oral contraceptive gestagen in ulcerative colitis before and after proctocolectomy and construction of a continent ileostomy. Contraception. 1985;31:195–204
  33. Rutgeerts L, Ghillebert G, Drognee W, Tanghe W, Vuylsteke P, Decoster M. Ischemic colitis in a patient with Crohn's disease taking an oral contraceptive and an ergotamine alkaloid. Acta Clin Belg. 1993;48:48–51
  34. Sutherland L, Ramcharan S, Bryant H, Fick G. Effect of oral contraceptive use on reoperation following surgery for Crohn's disease. Dig Dis Sci. 1992;37:1377–1382
  35. Timmer A, Sutherland LR, Martin F. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Oral contraceptive use and smoking are risk factors for relapse in Crohn's disease. Gastroenterology. 1998;114:1143–1150
  36. Wakeman J. Exacerbation of Crohn's disease after insertion of a levonorgestrel intrauterine system: a case report. J Fam Plann Reprod Health Care. 2003;29:154
  37. Wright JP. Factors influencing first relapse in patients with Crohn's disease. J Clin Gastroenterol. 1992;15:12–16
  38. Bitton A, Peppercorn M, Antonioli DA, et al. Clinical, biological, and histological parameters as predictors of relapse in ulcerative colitis. Gastroenterology. 2001;120:13–20
  39. Cox M, Tripp J, Blacksell S. Clinical performance of the levonorgestrel intrauterine system in routine use by the UK Family Planning and Reproductive Health Research Network: 5-year report. J Fam Plann Reprod Health Care. 2002;28:3–7
  40. Best W, Becktel J, Singleton J, Kern F. Development of a Crohn's disease activity index. Gastroenterology. 1976;70:439–444
  41. Stokkers PC, van Bodegraven AA. Vertebral deformities and inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2008;20:819–821
  42. Curtis KM, Martins S. Progestogen-only contraception and bone mineral density: a systematic review. Contraception. 2006;73:470–487
  43. Browne H, Manipalviratn S, Armstrong A. Using an intrauterine device in immunocompromised women. Obstet Gynecol. 2008;112:667–669
  44. Loftus EV. Management of extraintestinal manifestations and other complications of inflammatory bowel disease. Curr Gastroenterol Rep. 2004;6:506–513
  45. Rasmussen H, Fallingborg J, Mortensen P, Vyberg M, Tage-Jensen U, Rasmussen S. Hepatobiliary dysfunction and primary sclerosing cholangitis in patients with Crohn's disease. Scand J Gastroenterol. 1997;32:604–610

☆ Disclaimer: the findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S0010-7824(10)00056-9

doi: 10.1016/j.contraception.2010.02.012

Contraception
Volume 82, Issue 1 , Pages 72-85 , July 2010

Article Tools